科拓生物
(300858)
| 流通市值：27.80亿 | | | 总市值：37.42亿 |
| 流通股本：1.96亿 | | | 总股本：2.63亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 326,417,490.39 | 209,112,403.69 | 99,696,317.1 | 97,785,478.66 |
| 交易性金融资产 | 353,572,466.84 | 525,731,156.32 | 110,206,205.65 | 100,787,199.86 |
| 应收票据及应收账款 | 73,328,745.16 | 78,749,012.25 | 69,064,593.99 | 65,945,547.23 |
| 其中：应收票据 | - | - | - | 699,613.2 |
| 应收账款 | 73,328,745.16 | 78,749,012.25 | 69,064,593.99 | 65,245,934.03 |
| 应收款项融资 | 1,467,400 | 656,400 | 478,481.67 | - |
| 预付款项 | 18,188,978.59 | 10,681,436.35 | 5,665,002.53 | 18,364,191.05 |
| 其他应收款合计 | 1,155,253.58 | 1,094,289.88 | 1,129,214.96 | 755,895.89 |
| 存货 | 53,325,819.16 | 38,303,180.4 | 46,466,130.35 | 48,283,886.58 |
| 一年内到期的非流动资产 | 10,766,083.33 | 32,562,619.85 | 620,361,591.34 | 616,302,970.34 |
| 其他流动资产 | 11,573,681.15 | 23,734,368.02 | 24,270,312.44 | 27,103,490.21 |
| 流动资产合计 | 849,795,918.2 | 920,624,866.76 | 977,337,850.03 | 975,328,659.82 |
| 非流动资产: | | | | |
| 长期股权投资 | 25,232,019.24 | 24,581,958.4 | 22,800,486.77 | 22,250,937.77 |
| 其他权益工具投资 | 21,234,186 | 1,284,186 | 1,284,186 | 1,231,554 |
| 固定资产 | 796,195,246.97 | 363,698,928.55 | 371,284,047.5 | 353,548,257.71 |
| 在建工程 | 70,303,761.17 | 528,737,282.76 | 502,864,828.5 | 341,594,975.74 |
| 使用权资产 | 4,034,342.33 | 3,319,096.46 | 3,616,493.29 | 3,357,093.22 |
| 无形资产 | 58,783,819.76 | 59,419,813.29 | 60,102,231.46 | 60,216,443.67 |
| 商誉 | 1,913,334.43 | 1,913,334.43 | 1,913,334.43 | 1,913,334.43 |
| 长期待摊费用 | 1,366,460.96 | 1,524,129.53 | 1,681,798.1 | 7,584,129.45 |
| 递延所得税资产 | 17,579,577.4 | 14,672,176.73 | 13,009,728.75 | 4,616,674.21 |
| 其他非流动资产 | 181,739,406.05 | 107,533,251.41 | 63,013,905.76 | 169,217,394.43 |
| 非流动资产合计 | 1,178,382,154.31 | 1,106,684,157.56 | 1,041,571,040.56 | 965,530,794.63 |
| 资产总计 | 2,028,178,072.51 | 2,027,309,024.32 | 2,018,908,890.59 | 1,940,859,454.45 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 126,186,295.62 | 85,707,577.97 | 88,075,821.71 | 50,061,581.78 |
| 应付账款 | 126,186,295.62 | 85,707,577.97 | 88,075,821.71 | 50,061,581.78 |
| 合同负债 | 18,276,367.74 | 16,739,014.1 | 14,065,235.94 | 18,397,271.14 |
| 应付职工薪酬 | 6,454,488.7 | 5,167,405.33 | 14,689,627.9 | 4,997,194.73 |
| 应交税费 | 6,532,626.07 | 8,253,019.7 | 7,793,515.25 | 7,641,035.5 |
| 其他应付款合计 | 27,105,798.78 | 875,606.44 | 1,031,094.9 | 907,260.13 |
| 应付股利 | 26,016,511.8 | - | - | - |
| 一年内到期的非流动负债 | 851,889.44 | 808,304.92 | 785,068.13 | 700,988.78 |
| 其他流动负债 | 1,552,154.14 | 1,503,149.94 | 1,159,916.63 | 1,541,539.04 |
| 流动负债合计 | 186,959,620.49 | 119,054,078.4 | 127,600,280.46 | 84,246,871.1 |
| 非流动负债: | | | | |
| 租赁负债 | 2,655,243.93 | 2,437,953.01 | 2,800,876.52 | 2,681,060.32 |
| 递延收益 | 44,457,417.19 | 46,186,004.35 | 43,825,685.55 | 26,194,783.73 |
| 递延所得税负债 | 2,083,629.01 | 1,851,606.65 | 1,853,961.25 | 1,461,265.95 |
| 非流动负债合计 | 49,196,290.13 | 50,475,564.01 | 48,480,523.32 | 30,337,110 |
| 负债合计 | 236,155,910.62 | 169,529,642.41 | 176,080,803.78 | 114,583,981.1 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 263,495,118 | 263,495,118 | 263,495,118 | 263,495,118 |
| 资本公积 | 1,105,307,155.46 | 1,105,307,155.46 | 1,105,307,155.46 | 1,107,041,979.46 |
| 减:库存股 | 49,886,391.88 | - | - | - |
| 其他综合收益 | 6.67 | 6.87 | 11.51 | -21.25 |
| 盈余公积 | 59,209,225.34 | 59,209,225.34 | 59,209,225.34 | 57,702,020.68 |
| 未分配利润 | 413,897,048.3 | 429,767,876.24 | 414,816,576.5 | 398,036,376.46 |
| 归属于母公司股东权益合计 | 1,792,022,161.89 | 1,857,779,381.91 | 1,842,828,086.81 | 1,826,275,473.35 |
| 股东权益合计 | 1,792,022,161.89 | 1,857,779,381.91 | 1,842,828,086.81 | 1,826,275,473.35 |
| 负债和股东权益合计 | 2,028,178,072.51 | 2,027,309,024.32 | 2,018,908,890.59 | 1,940,859,454.45 |
| 公告日期 | 2026-08-24 | 2026-04-22 | 2026-04-22 | 2025-10-22 |
| 审计意见(境内) | | | 标准无保留意见 | |